A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.

Amar Miglani,Zachary M Soler,Timothy L Smith,Jess C Mace,Rodney J Schlosser

International forum of allergy & rhinology（2023）

引用 11|浏览7

暂无评分

摘要

At 24 weeks and 52 weeks, ESS offers comparable SNOT-22 improvements compared to dupilumab. ESS and dupilumab offer comparable improvement in smell identification at 24 weeks. Compared to omalizumab, ESS offers superior SNOT-22 improvements. ESS offers significantly greater reductions in polyp size compared to omalizumab, dupilumab, and mepolizumab therapies.

查看译文

关键词

chronic disease,chronic rhinosinusitis,endoscopic sinus surgery,eosinophilic rhinitis,nasal polyposis,outcome assessment (health care),quality of life,sinusitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要